Cancer risk after exposure to treatments for ovulation induction

American Journal of Epidemiology

Volumn 169, Issue 3, 2009, Pages 365-375

  Calderon Margalit, R ^a   Friedlander, Y ^a   Yanetz, R ^a   Kleinhaus, K ^b   Perrin, M C ^c   Manor, O ^a   Harlap, S ^c,d   Paltiel, O ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NewYork Presbyterian Hospital   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University ^*  (United States)

Author keywords

Breast neoplasms; Cohort studies; Incidence; Lymphoma, non Hodgkin; Melanoma; Ovarian neoplasms; Ovulation induction; Uterine neoplasms

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN;

CANCER; COHORT ANALYSIS; DISEASE INCIDENCE; DRUG; HEALTH RISK; REPRODUCTIVE CYCLE; TUMOR; WOMENS HEALTH;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLON CANCER; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FEMALE INFERTILITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MELANOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; OVULATION INDUCTION; PARITY; THYROID CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; BREAST TUMOR; EPIDEMIOLOGY; INCIDENCE; ISRAEL; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SKIN TUMOR; STATISTICS;

ASIA; EURASIA; ISRAEL; JERUSALEM [ISRAEL]; MIDDLE EAST;

ADULT; BREAST NEOPLASMS; CAUSALITY; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; ISRAEL; LYMPHOMA, NON-HODGKIN; MELANOMA; OVARIAN NEOPLASMS; OVULATION INDUCTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SKIN NEOPLASMS; UTERINE NEOPLASMS;

EID: 59649119037     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn318     Document Type: Article

References (46)

1. Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23. 2005:(25):1-160.
2. Juul S, Karmaus W, Olsen J. Regional differences in waiting time to pregnancy: pregnancy-based surveys from Denmark, France, Germany, Italy and Sweden. The European Infertility and Subfecundity Study Group. Hum Reprod. 1999;14(5):1250-1254.
3. Henne MB, Bundorf MK. Insurance mandates and trends in infertility treatments. Fertil Steril. 2008;89(1):66-73.
4. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril. 2004;82(suppl 1):S90-S96.
5. Vandewiele RL, Turksoy RN. Treatment of amenorrhea and of anovulation with human menopausal and chorionic gonadotropins. J Clin Endocrinol Metab. 1965;25:369-384.
6. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update. 2004;10(6):453-467.
7. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331(12):771-776.
8. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1184-1203.
9. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol. 2004;103(6):1194- 1203.
10. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160(11):1070-1078.
11. Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. Infertility, ovulation induction treatments and the incidence of breast cancer - a historical prospective cohort of Israeli women. Breast Cancer Res Treat. 2006;100(2):201-212.
12. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod. 2004;19(9):2005-2013.
13. Potashnik G, Lerner-Geva L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 1999;71(5):853-859.
14. Rossing MA, Daling JR, Weiss NS, et al. Risk of breast cancer in a cohort in infertile women. Gynecol Oncol. 1996;60(1):3-7.
15. Jensen A, Sharif H, Svare EI, et al. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1400-1407.
16. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586- 1590.
17. Brinton LA, Moghissi KS, Scoccia B, et al. Ovulation induction and cancer risk. Fertil Steril. 2005;83(2):261-274.
18. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11):1038-1042.
19. Harlap S, Davies AM, Deutsch L, et al. The Jerusalem Perinatal Study cohort, 1964-2005: methods and a review of the main results. Paediatr Perinat Epidemiol. 2007;21(3):256-273.
20. Balen AH, Braat DD, West C, et al. Cumulative conception and live birth rates after the treatment of anovulatory infertility: safety and efficacy of ovulation induction in 200 patients. Hum Reprod. 1994;9(8):1563-1570.
21. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod. 2002;17(8):2209-2213.
22. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol. 2004;92(1):320-326.
23. Kashyap S, Moher D, Fung MF, et al. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol. 2004;103(4):785-794.
24. Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol. 2005;161(7):607-615.
25. Benshushan A, Paltiel O, Brzezinski A, et al. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):53-57.
26. Parazzini F, Ricci E, Rosa C, et al. Risk of endometrial cancer after use of fertility drugs [letter]. Hum Reprod. 2001;16(1):196.
27. Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46(2):133-145.
28. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
29. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20(6):1511-1515.
30. Zhang Y, Holford TR, Leaderer B, et al. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. Am J Epidemiol. 2004;160(8):766-773.
31. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-Hodgkin's lymphoma in women. J Clin Oncol. 2001;19(5):1381-1387.
32. Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1466-1471.
33. Nørgaard M, Poulsen AH, Pedersen L, et al. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study. Br J Cancer. 2006;94(9):1339-1341.
34. Altieri A, Gallus S, Franceschi S, et al. Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev. 2004;13(4):349-351.
35. Althuis MD, Scoccia B, Lamb EJ, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol. 2005;193(3):668-674.
36. Hannibal CG, Jensen A, Sharif H, et al. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control. 2008;19(7):759-765.
37. Holly EA, Cress RD, Ahn DK. Cutaneousmelanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev. 1994;3(8):661-668.
38. Naldi L, Altieri A, Imberti GL, et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol. 2005;15(7):545-550.
39. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727.
40. Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2):237-243.
41. La Vecchia C, Negri E, Franceschi S, et al. Oral contraceptives and breast cancer: a cooperative Italian study. Int J Cancer. 1995;60(2):163-167.
42. Andersson M, Jensen MB, Engholm G, et al. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer Cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol. 2008;47(4):755-764.
43. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol. 2006;101(2):322-326.
44. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529-1542.
45. Matsuyama Y, Tominaga T, Nomura Y, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol. 2000;11(12):1537-1543.
46. Shapiro S. Risk of ovarian cancer after treatment for infertility [letter]. N Engl J Med. 1995;332(19):1301.